Sign In
Buy ZBH
$84.98
+1.23 (+1.47%)
At Close: Jun 03, 2026
Zimmer Biomet Receives CE Mark Approval for RibFix Advantage® Fixation System
07:30am, Tuesday, 01'st Apr 2025
Expanding Thoracic Portfolio WARSAW, Ind., and ZUG, Switzerland , April 1, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE: ZBH and SIX: ZBH), a global medical technology leader, today announ
3 Promising Surgical Robotics Stocks to Keep an Eye on in 2025
11:10am, Wednesday, 26'th Mar 2025
Investing in surgical robotics stocks like ISRG, ZBH and STXS can be profitable for investors in 2025.
Should You Consider Retaining ZBH Stock in Your Portfolio Now?
01:15pm, Friday, 21'st Mar 2025
Zimmer Biomet's robust Knee business appears promising. However, a dull macroeconomic condition adds to the worry.
Zimmer Biomet Focuses on Innovation Amid Growing Competition
10:55am, Friday, 14'th Mar 2025
Among Zimmer Biomet's knee solutions featured at the AAOS 2025, the newly cleared Persona Revision SoluTion Femur is expected to draw attention.
ZBH Stock to Gain From Global Expansion Amid Difficult FX Scenario
01:20pm, Wednesday, 12'th Mar 2025
Zimmer Biomet is strategically expanding its global presence to address the huge demand in the musculoskeletal space.
Paragon 28 Announces Expiration of HSR Act Waiting Period for Pending Acquisition by Zimmer Biomet Under HSR Act
04:01pm, Tuesday, 11'th Mar 2025
ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today
Zimmer Biomet Highlights Diverse Portfolio of Orthopedic & Musculoskeletal Innovations at AAOS 2025 Annual Meeting
07:30am, Monday, 10'th Mar 2025
Booth Spotlights Comprehensive Hip Portfolio, Newly Launched Knee and Upper Extremities Reconstructive Technologies, Including Recently Cleared Persona® Revision SoluTion™ Femur, and Debut of ZBX�
Zimmer Biomet Receives FDA Clearance for Persona® Revision SoluTion™ Femur
07:30am, Friday, 07'th Mar 2025
A Revision Knee Implant Alternative for Patients with Metal Sensitivities WARSAW, Ind., March 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology lea
Zimmer Biomet Names Kristen Cardillo as Senior Vice President, Chief Communications Officer
07:30am, Thursday, 06'th Mar 2025
WARSAW, Ind., March 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kristen Cardillo as Senior Vice Pr
Zimmer Biomet Launches You'll Be Back Campaign with Chief Movement Officer Arnold Schwarzenegger
07:30am, Wednesday, 26'th Feb 2025
Schwarzenegger Invites People Living with Joint Pain to Join New Online Community, Share Their Stories and Connect with a Qualified Physician WARSAW, Ind. , Feb. 26, 2025 /PRNewswire/ -- Zimmer Biomet
ZBH Stock Hurt by Margin Concerns and Difficult Solvency
11:56am, Monday, 17'th Feb 2025
Zimmer Biomet is suffering due to macroeconomic uncertainties, pricing pressure and unfavorable currency fluctuations.
Zimmer Biomet: Adding To The Growth Profile
06:45am, Friday, 07'th Feb 2025
Zimmer Biomet shares at $105 reveal value at 13 times adjusted earnings, as the company continues to grow despite a GLP-1 drug overhang. The 2015 Zimmer Biomet merger hasn't been fully delivered, but
ZBH's Q4 Earnings Beat, Margins Contract, Stock Down in Premarket
01:41pm, Thursday, 06'th Feb 2025
Zimmer Biomet benefits from its diversified portfolio outside of core orthopedics and the company's strategic investments in attractive, higher-growth segments.
Why Is Zimmer Biomet Stock Trading Lower On Thursday?
01:10pm, Thursday, 06'th Feb 2025
On Thursday, Zimmer Biomet Holdings, Inc ZBH reported fourth-quarter adjusted EPS of $2.31, up from $2.20 a year ago, beating the Street estimates of $2.30.
Zimmer Biomet Holdings, Inc. (ZBH) Q4 2024 Earnings Call Transcript
11:54am, Thursday, 06'th Feb 2025
Zimmer Biomet Holdings, Inc. (NYSE:ZBH ) Q4 2024 Earnings Conference Call February 6, 2025 8:30 AM ET Company Participants David DeMartino - Senior Vice President-Investor Relations Ivan Tornos - Pres
